Knoll Takeover Value Hinges On Outlook For D2E7 Rheumatoid Arthritis Agent
Knoll's valuation as a potential acquisition target appears to depend on assessments of the outlook for the anti-TNF monoclonal antibody D2E7.
Knoll's valuation as a potential acquisition target appears to depend on assessments of the outlook for the anti-TNF monoclonal antibody D2E7.